GlassScriptPhysician profile
Enrique J Gonzalez
NPI 1023161684
$5,261.91
in general payments reported to CMS, 2019-2025
38 companies · $485 in 2025
The $485 reported for 2025 was more than what 83% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.36 · 2020: $78.56 · 2021: $1,435 · 2022: $1,196 · 2023: $1,538 · 2024: $473 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $796.50 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $699.15 | 2020-2023 | Farxiga, Breztri, Fasenra |
| Lilly USA, LLC | $651.19 | 2020-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $493.03 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $429.69 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $308.10 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Amgen INC. | $287.35 | 2022-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $200.22 | 2022-2023 | Xarelto |
| Dexcom, INC. | $171.07 | 2022-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $162.35 | 2021-2022 | |
| Abbvie INC. | $161.15 | 2021-2023 | |
| Horizon Therapeutics Plc | $106.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.79 | 2021-2023 | |
| Gilead Sciences, INC. | $102.92 | 2020-2021 | |
| Eisai INC. | $50.93 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $46.37 | 2023 | Seglentis, Livalo |
| Biohaven Pharmaceuticals, INC. | $44.44 | 2021 | |
| Exact Sciences Corporation | $40.49 | 2025 | Cologuard Collection Kit |
| Mannkind Corporation | $39.60 | 2022-2023 | Afrezza |
| Viiv Healthcare Company | $38.09 | 2022-2023 | Dovato |
| Vbi Vaccine (Delaware) INC. | $36.67 | 2022-2023 | Prehevbrio |
| Boston Scientific Corporation | $34.14 | 2019 | |
| Ironwood Pharmaceuticals, INC | $28.27 | 2023 | Linzess |
| Abbott Laboratories | $28.11 | 2023 | Freestyle Libre 2 |
| Redhill Biopharma INC. | $26.81 | 2024 | Talicia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.50 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.43 | 2023 | Quviviq |
| Tersera Therapeutics LLC | $22.22 | 2019 | |
| Amarin Pharma, INC. | $21.85 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.93 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.00 | 2023 | Jynarque |
| Scilex Pharmaceuticals INC. | $18.37 | 2023 | Ztlido |
| Glaxosmithkline, LLC. | $16.62 | 2021 | |
| Inogen, INC. | $8.43 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enrique Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.